Table 3.

Univariable and multivariable analysis for overall survival.

Variable	Univariable Cox Regression Analysis			Cox Multivariable Regression
	HR	95% CI	p-Value	HR	95% CI	p-Value
Sex, Male vs. Female	1.584	0.935–2.683	0.087
Age, ≥65 vs. <65	1.061	0.793–1.420	0.688
ECOG, 1–2 vs. 0	0.980	0.739–1.299	0.887
Smoking History, Yes vs. No	1.168	0.864–1.578	0.314
BMI, kg/m2, ≥30 vs. <30	0..925	0.697–1.229	0.593
History of CAD, Yes vs. No	1.585	1.115–2.252	0.010
History of Hyperlipidemia, Yes vs. No	0.872	0.659–1.155	0.340
History of Hypertension, Yes vs. No	1.364	1.015–1.832	0.039
History of Diabetes, Yes vs. No	1.296	0.950–1.766	0.102
Tumor Location, Upper/Middle vs. Distal/GEJ	1.220	0.783–1.902	0.379
Pathology, SCC vs. Adenocarcinoma	1.364	0.896–2.076	0.148
Clinical Stage, III vs. I/II	1.863	1.353–2.564	0.000	1.850	1.332–2.571	<0.001
Induction Chemotherapy, Yes vs. No	0.879	0.655–1.180	0.390
Surgery, Yes vs. No	0.557	0.420–0.738	0.000	0.542	0.407–0.723	<0.001
Radiotherapy Technology, IMRT vs. PBT	1.047	0.776–1.411	0.764
PTV, ≥600 cc vs. <600 cc	1.319	0.995–1.748	0.054
Platin-based Chemotherapy, Yes vs. No	0.955	0.719–1.269	0.751
Mean LMA Dose, ≥20 Gy vs. <20 Gy	1.594	1.196	0.001	1.488	1.108–1.998	0.008

Abbreviations: CI, confidence interval; HR, hazard ratio; ECOG, Eastern Cooperative Oncology Group; BMI, body mass index; CAD, coronary artery disease; GEJ, gastroesophageal junction; SCC, squamous cell carcinoma; IMRT, intensity-modulated radiation therapy; PBT, proton beam therapy; PTV, Planning Target Volume; LMA, left main coronary artery.